Abstract
Hematopoietic stem cell transplantation (HSCT) has been used as curative treatment in both children and adults for hematologic malignancies, immunodeficiencies, autoimmune disorders, and other rare indications. While HSCT has revolutionized patient care, following HSCT, patients are at risk for several secondary cutaneous side effects. In this chapter, we discuss indications for HSCT, conditioning regimens before transplantation, and types of HSCTs. While there is a large range of cutaneous sequelae, we focus on three main topics and their histopathologic correlations in order to help practitioners identify them: (1) the different stages of acute and chronic cutaneous graft-versus-host disease as well as available treatment options; (2) the risk of cutaneous malignancies including nonmelanoma skin cancers and melanoma, as well as additional factors which may increase a patient’s risk; and (3) autoimmune and inflammatory skin diseases associated with HSCT. In transplant recipients, the diagnosis and management of acute and chronic skin diseases after HSCT are vital. We recommend full skin examinations annually and appropriate referral to dermatology when needed, especially in patients who may be at higher risk for skin cancer. Continued research is needed to better understand the pathogenesis and treatment of post-transplant effects on the skin.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gratwohl A, Baldomero H, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303(16):1617–24.
Vargas-Diez E, Fernandez-Herrera J, et al. Analysis of risk factors for acute cutaneous graft-versus-host disease after allogeneic stem cell transplantation. Br J Dermatol. 2003;148(6):1129–34.
Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813–26.
Inamoto Y, Storer BE, et al. Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. Blood. 2013;121(25):5098–103.
Kreutz M, Karrer S, et al. Whole-body UVB irradiation during allogeneic hematopoietic cell transplantation is safe and decreases acute graft-versus-host disease. J Invest Dermatol. 2012;132(1):179–87.
Cowen EW, Nguyen JC, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol. 2010;62(1):31–7.
Rork JF, Margossian SP, et al. Nonmelanoma skin cancer in childhood after hematopoietic stem cell transplant: a report of 4 cases. J Pediatr Hematol Oncol. 2013;36(3):224–7.
Lee SJ, Klein JP, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100(2):406–14.
Pidala J, Kim J, et al. The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. Haematologica. 2011a;96(11):1678–84.
Pidala J, Kurland B, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011b;117(17):4651–7.
Filipovich AH, Weisdorf D, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–56.
Hymes SR, Alousi AM, et al. Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease. J Am Acad Dermatol. 2012;66(4):515.e511–8; quiz 533–514.
Byun HJ, Yang JI, et al. Clinical differentiation of acute cutaneous graft-versus-host disease from drug hypersensitivity reactions. J Am Acad Dermatol. 2011;65(4):726–32.
Darmstadt GL, Donnenberg AD, et al. Clinical, laboratory, and histopathologic indicators of the development of progressive acute graft-versus-host disease. J Invest Dermatol. 1992;99(4):397–402.
Goiriz R, Penas P, et al. Stage IV cutaneous acute graft-versus-host disease. Clinical and histological study of 15 cases. J Eur Acad Dermatol Venereol. 2009;23(12):1398–404.
Kang HY, Kang WH. Leukomelanoderma following acute cutaneous graft-versus-host disease. Eur J Dermatol. 2004;14(3):146–9.
Chao SC, Tsao CJ, et al. Acute cutaneous graft-versus-host disease with ichthyosiform features. Br J Dermatol. 1998;139(3):553–5.
Huang J, Pol-Rodriguez M, et al. Acquired ichthyosis as a manifestation of acute cutaneous graft-versus-host disease. Pediatr Dermatol. 2007;24(1):49–52.
Matsushita T, Hasegawa M, et al. A case of acute cutaneous graft-versus-host disease mimicking psoriasis vulgaris. Dermatology. 2008;216(1):64–7.
Hahn T, McCarthy PL Jr, et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol. 2008;26(35):5728–34.
Jacobsohn DA. Acute graft-versus-host disease in children. Bone Marrow Transplant. 2008;41(2):215–21.
Jagasia M, Arora M, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119(1):296–307.
Godder KT, Hazlett LJ, et al. Partially mismatched related-donor bone marrow transplantation for pediatric patients with acute leukemia: younger donors and absence of peripheral blasts improve outcome. J Clin Oncol. 2000;18(9):1856–66.
Martin PJ, Rizzo JD, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18(8):1150–63.
Ozawa S, Nakaseko C, et al. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. Br J Haematol. 2007;137(2):142–51.
Arai S, Jagasia M, et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood. 2011;118(15):4242–9.
Shulman HM, Kleiner D, et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant. 2006;12(1):31–47.
Remberger M, Kumlien G, et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8(12):674–82.
Flowers ME, Inamoto Y, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214–9.
Wolff D, Schleuning M, et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17(1):1–17.
Edelson RL. Mechanistic insights into extracorporeal photochemotherapy: efficient induction of monocyte-to-dendritic cell maturation. Transfus Apher Sci. 2013;50(3):322–9.
Weitz M, Strahm B, et al. Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. Cochrane Database Syst Rev. 2014;2:CD009898.
Koc S, Leisenring W, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100(1):48–51.
Martin PJ, Storer BE, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009;113(21):5074–82.
Magro L, Mohty M, et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood. 2009;114(3):719–22.
Olivieri A, Locatelli F, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009;114(3):709–18.
Cutler C, Miklos D, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108(2):756–62.
Koreth J, Matsuoka K, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365(22):2055–66.
Lichter MD, Karagas MR, et al. Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group. Arch Dermatol. 2000;136(8):1007–11.
Schwartz JL, Kopecky KJ, et al. Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation. Radiat Res. 2009;171(2):155–63.
van Vloten WA, Hermans J, et al. Radiation-induced skin cancer and radiodermatitis of the head and neck. Cancer. 1987;59(3):411–4.
Leisenring W, Friedman DL, et al. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol. 2006;24(7):1119–26.
Majhail NS, Brazauskas R, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood. 2011;117(1):316–22.
Cavalier M, Shmalo JA, et al. Skin cancer after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplant. 2006;37(12):1103–8.
Rizzo JD, Curtis RE, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009;113(5):1175–83.
Curtis RE, Metayer C, et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood. 2005;105(10):3802–11.
Ades L, Guardiola P, et al. Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems. Blood Rev. 2002;16(2):135–46.
Deeg HJ, Socie G, et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood. 1996;87(1):386–92.
Fraser AG, Orchard TR, et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther. 2002;16(7):1225–32.
Feist A, Lee R, et al. Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole. J Heart Lung Transplant. 2012;31(11):1177–81.
Singer JP, Boker A, et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant. 2012;31(7):694–9.
Vadnerkar A, Nguyen MH, et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant. 2010;29(11):1240–4.
Zwald FO, Spratt M, et al. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. Dermatol Surg. 2012;38(8):1369–74.
Miller DD, Cowen EW, et al. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol. 2010;146(3):300–4.
Bhatia S, Ramsay NK, et al. Malignant neoplasms following bone marrow transplantation. Blood. 1996;87(9):3633–9.
Curtis RE, Rowlings PA, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336(13):897–904.
Socie G, Curtis RE, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol. 2000;18(2):348–57.
Borroni RG, Vassallo C, et al. Chronic graft-versus-host disease and non-melanoma skin cancer in children: report of two cases. Acta Derm Venereol. 2008;88(6):623.
Nathan PC, Ness KK, et al. Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the childhood cancer survivor study. Ann Intern Med. 2010;153(7):442–51.
Canninga-van Dijk MR, Sanders CJ, et al. Differential diagnosis of skin lesions after allogeneic haematopoietic stem cell transplantation. Histopathology. 2003;42(4):313–30.
Sherer Y, Shoenfeld Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant. 1998;22(9):873–81.
King C, Ilic A, et al. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell. 2004;117(2):265–77.
Trendelenburg M, Gregor M, et al. “Altered immunity syndrome”, a distinct entity in long-term bone marrow transplantation survivors? Bone Marrow Transplant. 2001;28(12):1175–6.
Daikeler T, Tyndall A. Autoimmunity following haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol. 2007;20(2):349–60.
Alajlan A, Alfadley A, et al. Transfer of vitiligo after allogeneic bone marrow transplantation. J Am Acad Dermatol. 2002;46(4):606–10.
Bellou A, Kanny G, et al. Transfer of atopy following bone marrow transplantation. Ann Allergy Asthma Immunol. 1997;78(5):513–6.
Kishimoto Y, Yamamoto Y, et al. Transfer of autoimmune thyroiditis and resolution of palmoplantar pustular psoriasis following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;19(10):1041–3.
Snowden JA, Heaton DC. Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity. Br J Dermatol. 1997;137(1):130–2.
Vialettes B, Maraninchi D. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet. 1993;342(8864):174.
Snowden JA, Atkinson K, et al. Allogeneic bone marrow transplantation from a donor with severe active rheumatoid arthritis not resulting in adoptive transfer of disease to recipient. Bone Marrow Transplant. 1997;20(1):71–3.
Bohgaki T, Atsumi T, et al. Autoimmune disease after autologous hematopoietic stem cell transplantation. Autoimmun Rev. 2008;7(3):198–203.
Au WY, Yeung CK, et al. Generalized vitiligo after lymphocyte infusion for relapsed leukaemia. Br J Dermatol. 2001;145(6):1015–7.
Burger J, Gmur J, et al. Epidermolysis bullosa acquisita, a rare late complication of allogeneic bone marrow transplantation? Bone Marrow Transplant. 1992;9(2):139–41.
Cathcart S, Morrell D. Vitiligo as a post-bone marrow transplantation complication. J Pediatr Hematol Oncol. 2007;29(7):485–7.
Daikeler T, Labopin M, et al. New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2013;121(6):1059–64.
Fullerton SH, Woodley DT, et al. Paraneoplastic pemphigus with autoantibody deposition in bronchial epithelium after autologous bone marrow transplantation. JAMA. 1992;267(11):1500–2.
Herr AL, Hatami A, et al. Successful anti-CD20 antibody treatment of pemphigus foliaceus after unrelated cord blood transplantation. Bone Marrow Transplant. 2005;35(4):427–8.
Olaguibel J, Almodovar A, et al. Passive transfer of contact sensitivity to colophony as a complication of an allogenic bone-marrow transplant. Contact Dermatitis. 1989;20(3):182–4.
Szabolcs P, Reese M, et al. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant. 2002;30(5):327–9.
Yong PF, Grosse-Kreul D, et al. Increase in allergy following donor lymphocyte infusions. Bone Marrow Transplant. 2006;37(10):983–4.
Nambudiri VE, Tsiaras WG, et al. Total leukoderma and leukotrichia in a child after hematopoietic SCT: report of a case and review of the literature. Bone Marrow Transplant. 2013;49:460.
Daikeler T, Gunaydin I, et al. Transmission of psoriatic arthritis by allogeneic bone marrow transplantation for chronic myelogenous leukaemia from an HLA-identical donor. Rheumatology (Oxford). 1999;38(1):89–90.
Hubiche T, Leaute-Labreze C, et al. Psoriasis after cord blood stem cell transplantation. Br J Dermatol. 2007;156(2):386–8.
Kanamori H, Tanaka M, et al. Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: case report and review of the literature. Am J Hematol. 2002;71(1):41–4.
Mori J, Kakihana K, et al. Sustained remission of psoriasis vulgaris after allogeneic bone marrow transplantation. Br J Haematol. 2012;159(2):121.
Patriarca F, Skert C, et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol. 2006;34(3):389–96.
Sanli H, Akay BN, et al. Vitiligo after hematopoietic cell transplantation: six cases and review of the literature. Dermatology. 2008;216(4):349–54.
Fleming JN, Shulman HM, et al. Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis. PLoS One. 2009;4(7):e6203.
Hiroki A, Nakamura S, et al. A comparison of glandular involvement between chronic graft-versus-host disease and Sjogren’s syndrome. Int J Oral Maxillofac Surg. 1996;25(4):298–307.
Delbaldo C, Rieckhoff-Cantoni L, et al. Bullous pemphigoid associated with acute graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1992;10(4):377–9.
Cotliar J, Frankfurt O. Demodex folliculitis mimicking acute graft-vs-host disease. JAMA Dermatol. 2013;149(12):1407–9.
Goiriz R, Guhl-Millan G, et al. Eosinophilic folliculitis following allogeneic peripheral blood stem cell transplantation: case report and review. J Cutan Pathol. 2007;34(Suppl 1):33–6.
Spelman LJ, Robertson IM, et al. Pityriasis rosea-like eruption after bone marrow transplantation. J Am Acad Dermatol. 1994;31(2 Pt 2):348–51.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Sheu, J., Nambudiri, V.E., Goddard, A.L., Huang, J.T., Saavedra, A.P. (2018). Skin Diseases Associated with Stem Cell Transplantation. In: Colegio, O. (eds) Skin Diseases in the Immunosuppressed. Springer, Cham. https://doi.org/10.1007/978-3-319-68790-2_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-68790-2_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-68788-9
Online ISBN: 978-3-319-68790-2
eBook Packages: MedicineMedicine (R0)